Korro Bio Inc. Ordinary Shares KRRO 深 沪
已收盘 12-19 16:00:00 美东时间
7.88
+0.060
+0.77%
华盛通- 最 高8.8299
- 今 开7.82
- 成交量 18.01万股
- 最 低 5.2044
- 昨 收 7.82
- 总市值 0
- 52周最高 55.89
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 5.2044
- 委 比 -98.89%
- 总股本 --
- 历史最高 98.00
- 量 比 0.72
- 振 幅 46.36%
- 历史最低 0.183
- 每 手 1
- 风险率 12.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Korro Bio Early Trial Results Fall Short; Stock Hits New Low
Korro Bio shares drop after KRRO-110 trial in AATD misses protein goals; company cuts 34% of staff and shifts focus to liver-targeted programs.
11-14 03:26
Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results
U.S. stocks traded lower midway through trading, with the Nasdaq Composite fall...
11-14 01:03
HC Wainwright & Co. Downgrades Korro Bio to Neutral
HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Korro Bio (NASDAQ:KRRO) from Buy to Neutral.
11-13 20:39
Why Cisco Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Shares of Cisco Systems, Inc. (NASDAQ:CSCO) rose sharply in pre-market trading ...
11-13 18:16
Korro Bio Announces Collaboration With Novo Nordisk To Develop Two Therapeutic Candidates, Leveraging Korro's Proprietary OPERA Platform To Enable Its Oligonucleotide-Directed RNA Edits Into Two Undisclosed Targets; Initially For Cardiometabolic Diseases; Total Deal Value Of Up To $530M In Upfront, Development, And Commercial Milestone Payments, In Addition To Tiered Royalties And R&D Funding
Partnership leverages Korro's proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; initially for cardiometabolic diseases Total deal value of up to $530 million
2024-09-16 20:12
